DHP Korea Co. Ltd (131030) - Cash Flow Conversion Efficiency
Based on the latest financial reports, DHP Korea Co. Ltd (131030) has a cash flow conversion efficiency ratio of 0.035x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩5.29 Billion ≈ $3.59 Million USD) by net assets (₩150.47 Billion ≈ $101.97 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See 131030 net asset quality score to measure how much of total assets are equity-financed.
DHP Korea Co. Ltd - Cash Flow Conversion Efficiency Trend (2014–2024)
This chart illustrates how DHP Korea Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of DHP Korea Co. Ltd to evaluate the quality of earnings relative to operating cash generation.
DHP Korea Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of DHP Korea Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Nice D&B Co. Ltd
KQ:130580
|
0.023x |
|
Datavan International
TWO:3521
|
-0.015x |
|
IXAQF
NASDAQ:IXAQF
|
0.078x |
|
KUYA SILVER CORP.
F:6MR1
|
N/A |
|
Atari S.A.
PA:ALATA
|
-0.412x |
|
Big Sunshine Co Ltd
TW:1475
|
0.122x |
|
ktcs corporation
KO:058850
|
-0.054x |
|
Drb Holding
KO:004840
|
-0.008x |
Annual Cash Flow Conversion Efficiency for DHP Korea Co. Ltd (2014–2024)
The table below shows the annual cash flow conversion efficiency of DHP Korea Co. Ltd from 2014 to 2024. For the full company profile with market capitalisation and key ratios, see market cap of DHP Korea Co. Ltd.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩143.73 Billion ≈ $97.41 Million |
₩8.90 Billion ≈ $6.03 Million |
0.062x | -33.03% |
| 2023-12-31 | ₩134.45 Billion ≈ $91.12 Million |
₩12.44 Billion ≈ $8.43 Million |
0.093x | +462.97% |
| 2022-12-31 | ₩124.47 Billion ≈ $84.35 Million |
₩2.05 Billion ≈ $1.39 Million |
0.016x | -70.48% |
| 2021-12-31 | ₩127.02 Billion ≈ $86.08 Million |
₩7.07 Billion ≈ $4.79 Million |
0.056x | -62.06% |
| 2020-12-31 | ₩118.88 Billion ≈ $80.57 Million |
₩17.45 Billion ≈ $11.82 Million |
0.147x | -6.05% |
| 2019-12-31 | ₩107.75 Billion ≈ $73.02 Million |
₩16.83 Billion ≈ $11.41 Million |
0.156x | -1.48% |
| 2018-12-31 | ₩94.90 Billion ≈ $64.31 Million |
₩15.05 Billion ≈ $10.20 Million |
0.159x | -25.02% |
| 2017-12-31 | ₩86.55 Billion ≈ $58.66 Million |
₩18.30 Billion ≈ $12.40 Million |
0.211x | +32.18% |
| 2016-12-31 | ₩75.26 Billion ≈ $51.00 Million |
₩12.04 Billion ≈ $8.16 Million |
0.160x | -5.44% |
| 2015-12-31 | ₩65.49 Billion ≈ $44.38 Million |
₩11.08 Billion ≈ $7.51 Million |
0.169x | -25.43% |
| 2014-12-31 | ₩56.49 Billion ≈ $38.28 Million |
₩12.82 Billion ≈ $8.69 Million |
0.227x | -- |
About DHP Korea Co. Ltd
OPTUS Pharmaceutical Co., Ltd. provides ophthalmic solutions in South Korea. The company offers dry eye preparation, antibiotics, anti-allergic preparation, steroids preparation, glaucoma treatment, and retinopathy treatment products. It also provides ETC, OTC, cosmetics, healthcare, and other products, as well as single-dose unit eye drops and eye care products under OEU& brand name. The company… Read more